AGF-39

Hair Mesotherapy Solution

Specially designed for Clinical use

Is it safe?

Approved by 7 Univ.Hospitals

Used by 500 major Hair treatment & Dermatology Clinics

Verified over 10 years and 1,000,000 clinical cases

Is it

effective?

The only one hair mesotherapy solution approved by SCI journal 

Journal of Dermatology 2012: 39:1-2

Research findings presented at World Congress for Hair research 2013 , Edinburgh, Scotland. P056

Research findings presented at World Congress for Hair research 2014 , Jeju, Korea. P180

"Effects of topical application of growth factors followed by microneedle therapy in women with female pattern hair loss"

"Effects of topical application of growth factors followed by microneedle therapy in women with female pattern hair loss"

The Journal of Dermatology 2012: 39:1-2

11 Korean women(41.36+2.43years) with FPHL.

The severity of FPHL was classified into the Ludwig grade I in all patients.

Random, Double-blind test. Growth factor solution(SGF57/AGF-39) was topically applied on the treated half of the scalp and followed by microneedle therapy. The other half of the scalp(control side) was treated with normal saline followed by microneedle therapy.

Results : The difference in hair shaft density were significant at the 2nd, 4th and 5th

weeks. The mean change in hair shaft count was measured which showed increase of more than 10% compared with baseline.

Conclusion : The present study provides a novel treatment option of FPHL, which is safe

and effective for enhancing hair density 

"Systemic growth factor treatment on the patients with androgenetic alopecia"

7th World Congress for Hair Research, 2013.5.4~6, Edinburg, Scotland

BI Ro, Dept. Dermatology, Myongji Hospital/Kwandong Univ.Korea

"Systemic growth factor treatment on the patients with androgenetic alopecia"

Purpose : The aim of this study is to evaluate the efficacy of systemic growth factor treatment in patients with AGA.

Methods : SGF-57(AGF-39) were topically applied using medical devices containing a microneedle and by electroporation in a 2-4week interval. The efficacy was evaluated after 10 treatments within 6 months. In total, 116 patients aged between 19 and 60 years were enrolled.

Results : Phototrichogram showed 9.85% increase in hair density and 9.11% increase in hair thickness. In hair density, 30.1% showed 5-10% increase, and 25% of the patients showed more than 15% increase. In hair thickness, 35.3% presented 0-5% increase, and 21.5% patients presented more than 15% increase.

Conclusion : Systemic growth factor therapy is effective and safe for the treatment of AGA and this will be one of the treatment options for AGA.  

"Comparison of Therapeutic Effect of Systematic Growth Factor

Microneedle Treatment in the Patients with Male Pattern Hair Loss by Varying Depth of Absorption"

8th World Congress for Hair Research, 2014.5.14~17, Jeju, Jeju island, Korea

BI Ro, Dept. Dermatology, Myongji Hospital, Goyang, Gyeonggido, Korea

Purpose : The aim of this study is to evaluate the efficacy, safety, and difference of effects of microneedle depth in treatment of patients with AGA.

Methods : Growth factor (HR Cytokains SGF-57(AGF-39); Aesmed, Seoul,Korea) were topically applied using medical devices containing a microneedle on patients with Male Pattern hair Loss(MPHL; 5 patients)III, IV, V and Female Pattern Hair Loss(FPHL; 6 patients) for 3 months period from Sep.2013 to Dec.2013. Split study was used: Dividing scalp by the right side and left side; Right side: 0.5mm depth of microneedle, Left side: 0.3mm depth of microneedle.

Results : In density, 0.5mm depth was more effective than 0.3mm significant in difference (p<0.05). In thickness, effect according to depth was not significant in difference(p>0,05)

Conclusion : Our results show that 0.5mm depth seems to be more effective than 0.3mm depth of microneedle  in treating patients of AGA using growth factor microneedle therapy.

"Comparison of Therapeutic Effect of Systematic Growth Factor

Microneedle Treatment in the Patients with Male Pattern Hair Loss by Varying Depth of Absorption"

Forte 2 vials (High Concentration) 20.5ppm

Basic 8 vials (Standard Concentration) 5.5ppm

1 box contains

22 weeks treatment

Intensive treatment with Forte vial for

first 3 weeks

Regular treatment with Basic vial for

8 weeks

Recommended program in clinics

(HR Cytokines Therapy)

Key ingredients

cytokines

  • bFGF  (basic-Fibroblast Growth Factor 9)

  • IGF-1  (Insulin-like Growth Factor-1)

  • KGF  (Keratinocyte Growth Factor)

  • VEGF  (Vascular Endothelial Growth Factor)

  • Noggin (Cytokine)

  • FGF-9 (Fibroblast Growth Factor 9)

  • SOD  (Superoxide Dismutase)

Vitmain B

Minerals

Amino acids

Coenzyme A

  • Coppertripeptide-3

  • Coenzyme A

  • Retinol(Vitamin A)

  • Thiamin HCL

  • Riboflavin

  • Niacinamide

  • Calcium pantothenate

  • Pyridoxine

  • Biotin

  • Cyanocobalamin

  • Folic Acid

  • Inositol

  • Magnesium Sulfate

  • Zinc oxide

  • Glutathione

  • Alanine

  • Arginine

  • Cysteine

  • Glutamine

  • Glycine

  • Histidine

  • Isoleucine

  • Leucine

  • Lysine

  • Methionine

  • Ornithine

  • Phenylalanine

  • Proline

  • Serine

  • Threonine

  • Tryptophan

  • Tyroine

  • Valine

  • Adenosine triphosphate

Recommended direction of use

step 1

Normal

Saline

Prepare ....

  • 5ml syringe needle

  • 1 vial of AGF39

  • Normal Saline

1 vial of AGF39

5ml syringe needle

step 2

Open the normal saline

step 3

Extract 5ml of

Normal saline with

syringe needle

step 4

Open the AGF39 vial cap

Insert syringe needle into AGF39 vial

step 5

step 6

Shake the AGF39 vial

step 7

Extract 2~2.5ml of AGF39 into the syringe needle

Insert the extracted 2~2.5ml of AGF39 into the vial tube

step 8

Apply AGF39 on the scalp by using MTS(Micro-needle Thredding System) 0.2mm needle depth

or derma roller

step 9